4e06764d-9cf1-4cff-ad67-4c5e472fbff5
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.300
- FATTY_ACID_METABOLISM+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- PANCREAS_BETA_CELLS+0.300
- PEROXISOME+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
- NOTCH_SIGNALING+0.200
- ADIPOGENESIS+0.100
- ANGIOGENESIS+0.100
- COAGULATION+0.100
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.300
- G2M_CHECKPOINT-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
- MITOTIC_SPINDLE-0.300
- PI3K_AKT_MTOR_SIGNALING-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
- APOPTOSIS-0.200
- E2F_TARGETS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-6937-01A-11R-2016-07 | — | — | 0.827 |
| 2 | TCGA-IQ-7631-01A-11R-2081-07 | — | — | 0.793 |
| 3 | SRR2775133 | — | — | 0.787 |
| 4 | BSR_05_0056_A4_S72 | — | C | 0.772 |
| 5 | BS_KZPR01BD | DNET | — | 0.772 |
| 6 | GSM6454744 | — | A | 0.758 |
| 7 | TCGA-78-7149-01A-11R-2039-07 | — | cohortA2 | 0.756 |
| 8 | TCGA-CV-7414-01A-11R-2081-07 | — | — | 0.754 |
| 9 | BSR_04_0128_A4_S78 | — | B | 0.752 |
| 10 | TCGA-62-A46V-01A-11R-A24H-07 | — | cohortA1 | 0.742 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |